Alissa Md is a dynamic Medical Director in Pharmacovigilance and Patient Safety at AbbVie, where she plays a pivotal role in ensuring the safety and efficacy of innovative therapies. With a robust background as a licensed medical physician and extensive pharmaceutical experience, Alissa leads critical...
Alissa Md is a dynamic Medical Director in Pharmacovigilance and Patient Safety at AbbVie, where she plays a pivotal role in ensuring the safety and efficacy of innovative therapies. With a robust background as a licensed medical physician and extensive pharmaceutical experience, Alissa leads critical safety initiatives across multiple product lines, including the developmental product ABBV-668 and the early clinical phase product ABBV-154 for Crohn’s Disease. Her expertise extends to overseeing safety strategies for collaborative compounds, demonstrating her ability to navigate complex regulatory landscapes and cross-company partnerships effectively.
Alissa's leadership style is characterized by her compassionate approach, where she fosters a collaborative and engaging environment that encourages open communication and problem-solving. She believes that a positive workplace culture enhances productivity and quality outcomes, akin to the principles of effective dog training. This philosophy not only motivates her team but also drives the successful execution of safety strategies that align with AbbVie's commitment to patient welfare.
In her role, Alissa is responsible for defining and leading the pharmacovigilance strategy for post-marketing products, including the blockbuster Humira. Her proficiency in utilizing advanced tools like Veeva Vault and her strong analytical skills enable her to manage multiple product launches seamlessly while ensuring compliance with regulatory requirements. Alissa’s dedication to patient safety, combined with her strong communication skills and motivational leadership, positions her as a key player in advancing AbbVie’s mission to deliver high-quality, safe, and effective therapies to patients worldwide.
